Summary: Alkermes reported its Q2 2024 financial performance and advances in the development of narcolepsy treatments, particularly with the investigational drug ALKS 2680. The company highlighted its financial position, double-digit growth, and progress in its neuroscience … [Read more...]
Avadel Reports Uptick in Lumryz Therapy Adoption for Narcolepsy
Summary: Avadel Prescription drugs reported a considerable improve in Lumryz use for narcolepsy, with around 1,700 individuals initiating therapy—a 70% rise considering the fact that December. The enterprise is searching to expand Lumryz’s indications into pediatric treatment … [Read more...]
Oral Device Maker ProSomnus Reports Record Revenue for 2023
Summary: ProSomnus Inc, specializing in oral appliance remedy for obstructive slumber apnea, claimed a 43% enhance in 2023 income to $27.7 million, marking its eighth consecutive quarter of history earnings. Development was attributed to the adoption of its EVO item, elevated … [Read more...]
Zevra Reports Positive Phase 2 Results for IH Drug Candidate
Summary: The stage 2 scientific trial of KP1077 by Zevra Therapeutics for treating idiopathic hypersomnia (IH) has yielded good leading-line effects, confirming the drug’s security and tolerability. KP1077 demonstrated important enhancements in indications these as too much … [Read more...]